Aravive Investor Presentation Deck

Batiraxcept + Gemcitabine + nab-Paclitaxel Phase 1b/2 Trial Design in 1L Pancreatic Adenocarcinoma (NCT04983407) P1b Population: Patients (N-20) with advanced or metastatic pancreatic adenocarcinoma eligible to receive gemcitabine + nab- paclitaxel (Abraxane) as first-line treatment Phase 1b Batiraxcept 15 mg/kg on Days 1 & 15 plus Nab-Paclitaxel: 125 mg/m² on Days 1, 8, & 15 and Gemcitabine: 1000 mg/m² on Days 1, 8, & 15 (n=20*) 1:1 Initiation of P2 will be based on clinical activity in Ph1b Phase 2 Arm A: Batiraxcept plus Nab-Paclitaxel and Gemcitabine (n=30) Arm B: Nab-Paclitaxel and Gemcitabine (n=30) 29

View entire presentation